GLP-1 medications like Ozempic, Wegovy, and Zepbound are among the most discussed drugs in modern medicine. They aid weight loss, improve blood sugar, and may reduce cardiovascular risk.
But new research suggests the blockbuster drugs may come with a less visible downside: a higher risk of bone problems.
A 30% Higher Risk in the Study
In a new observational analysis, researchers found that about 4% of GLP-1 users with obesity and Type 2 diabetes developed osteoporosis, compared with just over 3% of people not taking the drugs.
That difference translates to roughly a 30% higher relative risk.
Osteoporosis weakens bones by reducing bone density and mass, making fractures far more likely. In the United States, about 10 million adults over age 50 already live with the condition, and more than 40 million have low bone density that could progress to osteoporosis.
The study also found that osteomalacia — a related disorder that softens bones — appeared about twice as often among GLP-1 users.
Why Bone Health Might Be Affected
Scientists are still working to understand the link, but several factors may play a role.
Rapid weight loss
When body weight drops quickly, the skeleton carries less load. Bone tissue responds to mechanical stress, so reduced weight can signal the body to maintain less bone density.
Lower nutrient intake
Because GLP-1 drugs suppress appetite, some users may eat fewer foods rich in calcium, vitamin D, and protein, nutrients essential for maintaining bone strength.
Hormonal shifts
Bone health is particularly sensitive to hormonal changes. Women approaching menopause already face declining estrogen levels, which accelerate bone loss. Rapid weight reduction during this life stage may compound the effect.
The Research Is Still Early
The study was observational, meaning it could identify associations but could not prove cause and effect. Researchers also did not measure factors such as diet quality, physical activity, or vitamin supplementation — all of which strongly influence bone health.
However, the findings align with other recent research linking GLP-1 medications to a higher risk of osteoporosis-related fractures in older adults with Type 2 diabetes.
The FDA already lists increased fracture risk in older adults and women on the labeling for semaglutide, the active ingredient in Ozempic and Wegovy.
What Experts Say Patients Should Focus On
Doctors emphasize that the potential risks should not overshadow the well-documented benefits of GLP-1 therapies. Instead, the findings highlight the importance of protecting bone health while using the medications.
Strategies that support bone strength include:
Weight-bearing exercise, such as walking, resistance training, or stair climbing
Adequate protein intake
Calcium-rich foods
Vitamin D from diet or sunlight
Regular monitoring of bone density in higher-risk patients
Researchers also observed a 12% higher risk of gout among GLP-1 users, likely related to temporary increases in uric acid during rapid weight loss.
The Bottom Line
GLP-1 drugs remain powerful tools for treating obesity and Type 2 diabetes. But as their popularity grows, scientists are beginning to map out their long-term effects more carefully.
The emerging message is simple: successful weight loss should also include strategies that protect muscle, nutrition, and bone health.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. It should not be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting, stopping or changing any medication or treatment.
